240 related articles for article (PubMed ID: 22948878)
1. Mode of action, in vitro activity, and in vivo efficacy of AFN-1252, a selective antistaphylococcal FabI inhibitor.
Kaplan N; Albert M; Awrey D; Bardouniotis E; Berman J; Clarke T; Dorsey M; Hafkin B; Ramnauth J; Romanov V; Schmid MB; Thalakada R; Yethon J; Pauls HW
Antimicrob Agents Chemother; 2012 Nov; 56(11):5865-74. PubMed ID: 22948878
[TBL] [Abstract][Full Text] [Related]
2. AFN-1252, a FabI inhibitor, demonstrates a Staphylococcus-specific spectrum of activity.
Karlowsky JA; Kaplan N; Hafkin B; Hoban DJ; Zhanel GG
Antimicrob Agents Chemother; 2009 Aug; 53(8):3544-8. PubMed ID: 19487444
[TBL] [Abstract][Full Text] [Related]
3. Resistance to AFN-1252 arises from missense mutations in Staphylococcus aureus enoyl-acyl carrier protein reductase (FabI).
Yao J; Maxwell JB; Rock CO
J Biol Chem; 2013 Dec; 288(51):36261-71. PubMed ID: 24189061
[TBL] [Abstract][Full Text] [Related]
4. AFN-1252 is a potent inhibitor of enoyl-ACP reductase from Burkholderia pseudomallei--Crystal structure, mode of action, and biological activity.
Rao KN; Lakshminarasimhan A; Joseph S; Lekshmi SU; Lau MS; Takhi M; Sreenivas K; Nathan S; Yusof R; Abd Rahman N; Ramachandra M; Antony T; Subramanya H
Protein Sci; 2015 May; 24(5):832-40. PubMed ID: 25644789
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics, pharmacodynamics and efficacy of novel FabI inhibitor AFN-1252 against MSSA and MRSA in the murine thigh infection model.
Banevicius MA; Kaplan N; Hafkin B; Nicolau DP
J Chemother; 2013 Feb; 25(1):26-31. PubMed ID: 23433441
[TBL] [Abstract][Full Text] [Related]
6. Activity of AFN-1252, a novel FabI inhibitor, against Staphylococcus aureus in an in vitro pharmacodynamic model simulating human pharmacokinetics.
Tsuji BT; Harigaya Y; Lesse AJ; Forrest A; Ngo D
J Chemother; 2013 Feb; 25(1):32-5. PubMed ID: 23433442
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of AFN-1252, the First Staphylococcus-Specific Antibacterial Agent, in the Treatment of Acute Bacterial Skin and Skin Structure Infections, Including Those in Patients with Significant Comorbidities.
Hafkin B; Kaplan N; Murphy B
Antimicrob Agents Chemother; 2015 Dec; 60(3):1695-701. PubMed ID: 26711777
[TBL] [Abstract][Full Text] [Related]
8. The MUT056399 inhibitor of FabI is a new antistaphylococcal compound.
Escaich S; Prouvensier L; Saccomani M; Durant L; Oxoby M; Gerusz V; Moreau F; Vongsouthi V; Maher K; Morrissey I; Soulama-Mouze C
Antimicrob Agents Chemother; 2011 Oct; 55(10):4692-7. PubMed ID: 21825292
[TBL] [Abstract][Full Text] [Related]
9. In vitro activity (MICs and rate of kill) of AFN-1252, a novel FabI inhibitor, in the presence of serum and in combination with other antibiotics.
Kaplan N; Awrey D; Bardouniotis E; Berman J; Yethon J; Pauls HW; Hafkin B
J Chemother; 2013 Feb; 25(1):18-25. PubMed ID: 23433440
[TBL] [Abstract][Full Text] [Related]
10. Perturbation of Staphylococcus aureus gene expression by the enoyl-acyl carrier protein reductase inhibitor AFN-1252.
Parsons JB; Kukula M; Jackson P; Pulse M; Simecka JW; Valtierra D; Weiss WJ; Kaplan N; Rock CO
Antimicrob Agents Chemother; 2013 May; 57(5):2182-90. PubMed ID: 23459481
[TBL] [Abstract][Full Text] [Related]
11. In vitro activity of API-1252, a novel FabI inhibitor, against clinical isolates of Staphylococcus aureus and Staphylococcus epidermidis.
Karlowsky JA; Laing NM; Baudry T; Kaplan N; Vaughan D; Hoban DJ; Zhanel GG
Antimicrob Agents Chemother; 2007 Apr; 51(4):1580-1. PubMed ID: 17220418
[No Abstract] [Full Text] [Related]
12. Bone and Joint Tissue Penetration of the
Menetrey A; Janin A; Pullman J; Overcash JS; Haouala A; Leylavergne F; Turbe L; Wittke F; Nicolas-Métral V
Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30559136
[TBL] [Abstract][Full Text] [Related]
13. CG400462, a new bacterial enoyl-acyl carrier protein reductase (FabI) inhibitor.
Park HS; Yoon YM; Jung SJ; Yun IN; Kim CM; Kim JM; Kwak JH
Int J Antimicrob Agents; 2007 Nov; 30(5):446-51. PubMed ID: 17723291
[TBL] [Abstract][Full Text] [Related]
14. Complestatin exerts antibacterial activity by the inhibition of fatty acid synthesis.
Kwon YJ; Kim HJ; Kim WG
Biol Pharm Bull; 2015; 38(5):715-21. PubMed ID: 25947917
[TBL] [Abstract][Full Text] [Related]
15. Chalcomoracin and moracin C, new inhibitors of Staphylococcus aureus enoyl-acyl carrier protein reductase from Morus alba.
Kim YJ; Sohn MJ; Kim WG
Biol Pharm Bull; 2012; 35(5):791-5. PubMed ID: 22687419
[TBL] [Abstract][Full Text] [Related]
16. Enoyl-Acyl Carrier Protein Reductase I (FabI) Is Essential for the Intracellular Growth of Listeria monocytogenes.
Yao J; Ericson ME; Frank MW; Rock CO
Infect Immun; 2016 Dec; 84(12):3597-3607. PubMed ID: 27736774
[TBL] [Abstract][Full Text] [Related]
17. Type II fatty acid synthesis is essential for the replication of Chlamydia trachomatis.
Yao J; Abdelrahman YM; Robertson RM; Cox JV; Belland RJ; White SW; Rock CO
J Biol Chem; 2014 Aug; 289(32):22365-76. PubMed ID: 24958721
[TBL] [Abstract][Full Text] [Related]
18. A FASII Inhibitor Prevents Staphylococcal Evasion of Daptomycin by Inhibiting Phospholipid Decoy Production.
Pee CJE; Pader V; Ledger EVK; Edwards AM
Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30718253
[TBL] [Abstract][Full Text] [Related]
19. Antistaphylococcal activities of CG400549, a new bacterial enoyl-acyl carrier protein reductase (FabI) inhibitor.
Park HS; Yoon YM; Jung SJ; Kim CM; Kim JM; Kwak JH
J Antimicrob Chemother; 2007 Sep; 60(3):568-74. PubMed ID: 17606482
[TBL] [Abstract][Full Text] [Related]
20. Discovery of a novel and potent class of FabI-directed antibacterial agents.
Payne DJ; Miller WH; Berry V; Brosky J; Burgess WJ; Chen E; DeWolf WE; Fosberry AP; Greenwood R; Head MS; Heerding DA; Janson CA; Jaworski DD; Keller PM; Manley PJ; Moore TD; Newlander KA; Pearson S; Polizzi BJ; Qiu X; Rittenhouse SF; Slater-Radosti C; Salyers KL; Seefeld MA; Smyth MG; Takata DT; Uzinskas IN; Vaidya K; Wallis NG; Winram SB; Yuan CC; Huffman WF
Antimicrob Agents Chemother; 2002 Oct; 46(10):3118-24. PubMed ID: 12234833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
